VITRO DIAGNOSTICS, INC. (OTCMKTS:VODG) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersITEM 5.02
ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN
On May 26, 2017, John R. Evans, age 62, was elected to serve as a member of the Board of Directors of the Company and appointed to the position of Chief Financial Officer. Biographical information regarding Mr. Evans can be found in the Company’s Current Report on Form 8-K dated March 23, 2017, previously filed with the commission on March 29, 2017.
Mr. Evans will continue to receive his consulting fee of $10,000 per month, as previously reported
About VITRO DIAGNOSTICS, INC. (OTCMKTS:VODG)
Vitro Diagnostics, Inc., doing business as Vitro Biopharma, is engaged in the development, manufacturing and distribution of stem cell products and related tools for use in research, drug discovery and clinical trials. The Company’s clinical products include clinical grade MSC-Gro for mesenchymal stem cell (MSC) expansion prior to transplantation; an equine MSC cell line with application to treatment of skeletal muscular conditions, such as tendonitis, ligament injury, osteoarthritis and accelerated bone fracture healing, and others; testing and therapies related to endogenous stem cell activation; diagnostic testing of stem cell activation and determination of stem cell functional status, and cell-based assays for discovery of stem cell activation agents and new drugs for the treatment of osteoporosis. The Company offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells. VITRO DIAGNOSTICS, INC. (OTCMKTS:VODG) Recent Trading Information
VITRO DIAGNOSTICS, INC. (OTCMKTS:VODG) closed its last trading session 00.0000 at 0.0800 with 21,832 shares trading hands.